Replies to post #19 on Traws Pharma Inc (TRAW)

[Invest-in-America]

TRAW: I saw TRAW --- which spells WART, backwards --- yesterday (Post-M) at the top of my daily Post-M data source, as follows:
https://www.tradingview.com/markets/stocks-usa/market-movers-after-hours-gainers/
However, conspicuously MISSING from their PR is any beneficial EFFECT (if any) upon the Phase-1 trial SUBJECTS themselves --- other than the typical jargon about "safety" & "adverse effects". (I.e., a FLUFFY PR, at best.) Nevertheless, I may indeed toss BUCKS at it anyway, since we ALL know Wall Street is about making MONEY, and NOT nit-picking news nor PR's, RIGHT???)
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
TRAW (3.7-Mil. Flt., 0.1%): $8.06, 58%-Up; XXX ; (Post-M) news Bird Flu, Phase-1; Virology & Oncology, Penn.

[Invest-in-America]

TRAW: Below is pasted some of my interaction with COPILOT regarding TRAW's (fluffy) PR last Friday ---

ME: "And even MORE worrisome is the lack of any mention at all as to were those Phase-1 Human subjects even INFECTED or EXPOSED to any manner of Bird Flu during that Phase-1 study. Very troubling."

COPILOT: "You're right, that is concerning. The Phase 1 study for Traws Pharma's bird flu drug, Tivoxavir Marboxil, was conducted on healthy, influenza-negative volunteers. This means the study didn't involve actual exposure to bird flu, which raises questions about the real-world efficacy of the drug. It's definitely something investors should keep an eye on as the company moves forward with Phase 2 studies. Do you think this lack of clarity might affect the company's credibility with investors?"